|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H3F3B |
Gene summary for H3F3B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H3F3B | Gene ID | 3021 |
| Gene name | H3.3 histone B | |
| Gene Alias | H3-3A | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | B2R4P9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3021 | H3F3B | F034 | Human | Colorectum | FAP | 3.24e-03 | -1.65e-01 | -0.0665 |
| 3021 | H3F3B | AEH-subject1 | Human | Endometrium | AEH | 5.16e-16 | -2.77e-01 | -0.3059 |
| 3021 | H3F3B | AEH-subject2 | Human | Endometrium | AEH | 3.06e-02 | -1.81e-01 | -0.2525 |
| 3021 | H3F3B | AEH-subject3 | Human | Endometrium | AEH | 5.24e-06 | -1.92e-01 | -0.2576 |
| 3021 | H3F3B | AEH-subject4 | Human | Endometrium | AEH | 1.23e-05 | -2.69e-01 | -0.2657 |
| 3021 | H3F3B | AEH-subject5 | Human | Endometrium | AEH | 2.13e-37 | -6.34e-01 | -0.2953 |
| 3021 | H3F3B | EEC-subject1 | Human | Endometrium | EEC | 1.67e-23 | -4.89e-01 | -0.2682 |
| 3021 | H3F3B | EEC-subject2 | Human | Endometrium | EEC | 7.90e-49 | -5.64e-01 | -0.2607 |
| 3021 | H3F3B | EEC-subject3 | Human | Endometrium | EEC | 1.24e-34 | -6.17e-01 | -0.2525 |
| 3021 | H3F3B | EEC-subject4 | Human | Endometrium | EEC | 4.32e-09 | -2.70e-01 | -0.2571 |
| 3021 | H3F3B | EEC-subject5 | Human | Endometrium | EEC | 7.92e-18 | -3.77e-01 | -0.249 |
| 3021 | H3F3B | GSM5276934 | Human | Endometrium | EEC | 5.27e-05 | -1.52e-01 | -0.0913 |
| 3021 | H3F3B | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 7.53e-11 | -1.12e-01 | -0.1869 |
| 3021 | H3F3B | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.58e-18 | -2.13e-01 | -0.1875 |
| 3021 | H3F3B | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.89e-23 | -2.07e-01 | -0.1883 |
| 3021 | H3F3B | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.07e-15 | -2.71e-01 | -0.1934 |
| 3021 | H3F3B | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.30e-29 | -8.28e-02 | -0.1917 |
| 3021 | H3F3B | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.52e-25 | -1.81e-01 | -0.1916 |
| 3021 | H3F3B | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.90e-06 | -1.84e-01 | -0.1269 |
| 3021 | H3F3B | LZE2D | Human | Esophagus | HGIN | 1.13e-11 | 2.44e+00 | 0.0642 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa0513125 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
| hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa0513135 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| H3F3B | SNV | Missense_Mutation | novel | c.292N>A | p.Glu98Lys | p.E98K | P84243 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.817) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| H3F3B | SNV | Missense_Mutation | rs11547396 | c.122G>A | p.Arg41His | p.R41H | P84243 | protein_coding | tolerated_low_confidence(0.09) | benign(0.001) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| H3F3B | SNV | Missense_Mutation | c.142N>A | p.Ala48Thr | p.A48T | P84243 | protein_coding | deleterious_low_confidence(0.03) | benign(0.011) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| H3F3B | SNV | Missense_Mutation | novel | c.200N>T | p.Pro67Leu | p.P67L | P84243 | protein_coding | deleterious_low_confidence(0.01) | benign(0.111) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| H3F3B | SNV | Missense_Mutation | novel | c.176N>T | p.Thr59Ile | p.T59I | P84243 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.792) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| H3F3B | SNV | Missense_Mutation | novel | c.199N>T | p.Pro67Ser | p.P67S | P84243 | protein_coding | deleterious_low_confidence(0.02) | benign(0.047) | TCGA-D1-A2G0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| H3F3B | SNV | Missense_Mutation | c.262G>A | p.Ala88Thr | p.A88T | P84243 | protein_coding | tolerated_low_confidence(0.16) | benign(0.023) | TCGA-44-6778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| H3F3B | SNV | Missense_Mutation | novel | c.379N>G | p.Leu127Val | p.L127V | P84243 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.999) | TCGA-50-6591-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| H3F3B | SNV | Missense_Mutation | c.79N>G | p.Arg27Gly | p.R27G | P84243 | protein_coding | deleterious_low_confidence(0.03) | benign(0.001) | TCGA-21-5784-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| H3F3B | SNV | Missense_Mutation | novel | c.258G>T | p.Gln86His | p.Q86H | P84243 | protein_coding | deleterious_low_confidence(0) | benign(0.091) | TCGA-37-3792-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |